Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study.

Schlesinger N, De Meulemeester M, Pikhlak A, Yücel AE, Richard D, Murphy V, Arulmani U, Sallstig P, So A.

Arthritis Res Ther. 2011 Mar 25;13(2):R53. doi: 10.1186/ar3297.

2.

Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study.

So A, De Meulemeester M, Pikhlak A, Yücel AE, Richard D, Murphy V, Arulmani U, Sallstig P, Schlesinger N.

Arthritis Rheum. 2010 Oct;62(10):3064-76. doi: 10.1002/art.27600.

3.

[Monoclonal antibodies IGR to surface antigens of neutrophilic granulocytes in human blood].

Ingerpuu SO, Piĭrsoo AO, Siunter AE, Pikhlak AN.

Eksp Onkol. 1990;12(1):56-60. Russian.

PMID:
2298145
4.

[Chondrocalcinosis: nosologic boundaries, diagnosis, prevalence].

Pikhlak AE, Tokmachev IuK.

Revmatologiia (Mosk). 1985 Oct-Dec;(4):3-9. Russian. No abstract available.

PMID:
3912892

Supplemental Content

Loading ...
Support Center